Français
Toutes les langues
05/11/2026 03:10
SENSAI VERITAS
EQS-News: SensAI Veritas Launches SensAI Gateway™ and SensAI Helm™: Bringing Risk Intelligence to the Moment of Trust
05/11/2026 00:02
NEXTDC LIMITED
EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
04/11/2026 23:10
UR-ENERGY INC.
Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
04/11/2026 23:00
AVINO SILVER & GOLD MINES LTD.
Avino Reports Q3 2026 Financial Results
04/11/2026 23:00
VIEMED HEALTHCARE, INC.
Viemed Healthcare Announces Third Quarter 2026 Financial Results
04/11/2026 22:41
RUBIS
Rubis: Assemblée Générale Mixte du 9 décembre 2026 – Modalités de mise à disposition des documents préparatoires
04/11/2026 22:41
RUBIS
Rubis: 9 December 2026 Combined Shareholders’ Meeting – Availability of the preparatory documents
04/11/2026 22:30
COTY INC
Inside Information / News release on accounts, results
04/11/2026 22:15
ZOMEDICA CORP.
Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
04/11/2026 22:05
STABILIS SOLUTIONS
Stabilis Solutions Announces Third Quarter 2026 Results
04/11/2026 19:41
SNP SCHNEIDER-NEUREITHER & PARTNER AG
EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
04/11/2026 19:25
MENARINI INDUSTRIE FARMACEUTICHE RIUNITE
EQS-News: Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
«
151
152
153
154
155
156
157
158
159
160
161
source :
webdisclosure.com